Robert Darrell Snow

US Patent:

6696084, Feb 24, 2004

Filed:

Apr 20, 2001

Appl. No.:

09/838593

Inventors:

Gary W. Pace - Winchester MA
Awadesh K. Mishra - Quebec, CA
Robert A. Snow - West Chester PA
Indu Parikh - Durham NC
Pol-Henri W. Guivarch - Quebec, CA

Assignee:

RTP Pharma Inc. - Durham NC

International Classification:

A61K 914

US Classification:

424451, 424458, 424464, 424469, 424470, 424489, 424490, 2523635

Abstract:

The present invention relates to a novel spray drying process for the preparation of pharmaceutical compositions containing small particles of phospholipid-stabilized fenofibrate. This invention also relates to spray dried powdered compositions prepared according to this process, and to dosage forms of fenofibrate (capsules, tablets, powders, granules, and dispersions) prepared from these powdered compositions. The powdered compositions and dosage forms are useful in the treatment of dyslipidemia and dyslipoproteinemia and have the advantage that they provide reduced in vivo variability in the bioavailability of fenofibrate active species among fed and fasted patients when administered orally.

US Patent:

6726919, Apr 27, 2004

Filed:

Jun 14, 2001

Appl. No.:

09/880104

Inventors:

Gary W. Pace - Winchester MA
Michael G. Vachon - Quebec, CA
Awadesh K. Mishra - Quebec, CA
Robert A. Snow - West Chester PA

Assignee:

RTP Pharma, Inc. - Durham NC

International Classification:

A61F 1300

US Classification:

424422, 424451, 424489, 424642, 424643, 514487, 514731

Abstract:

A sterile, injectable homogenized dispersion of micromatrices or microdroplets having a mean diameter from about 50 nm to about 1000 nm comprising about 1% to about 7. 5% of propofol, about 1% to about 8% of a propofol-soluble diluent, and about 0. 67% to about 5% of a surface stabilizing amphiphilic agent suspended in an aqueous medium containing a synergetic quantity of antimicrobial agent and a tonicity modifying amount of a pharmaceutically acceptable water-soluble hydroxyl-group-containing excipient, wherein the ratio of propofol to diluent is in the range of about 0. 25 to about 7. 5 while the ratio of propofol to amphiphilic agent is in the range from about 0. 4 to about 1. 5, and wherein the viscosity of the dispersion is in the range of 1. 1 to 8 cps, processes for the formation of the dispersion, and methods of use are disclosed.

US Patent:

7735845, Jun 15, 2010

Filed:

Aug 1, 2008

Appl. No.:

12/221251

Inventors:

Robert K. Snow - Kernersville NC, US

International Classification:

B62D 7/16

US Classification:

280 9351

Abstract:

A rear steer mower having a front steering assembly is provided. The front steering assembly includes a steering wheel, a steering shaft, a pair of toed out negatively castered front wheels and a linking element configured to receive rotational input from the steering wheel to the pair of front wheels.

US Patent:

20030194442, Oct 16, 2003

Filed:

May 19, 2003

Appl. No.:

10/440368

Inventors:

Pol-Henri Guivarch - Montreal, CA
Gary Pace - Winchester MA, US
Robert Snow - West Chester PA, US
Awadesh Mishra - Montreal, CA

Assignee:

SKYEPHARMA CANADA INC - Verdun

International Classification:

A61K009/14
A61K031/192

US Classification:

424/489000, 514/571000

Abstract:

This invention discloses an orally administered pharmaceutical composition comprising microparticles of solid fenofibrate that are stabilized by a phospholipid surface active substance that is present during the preparation of the microparticles, wherein a therapeutically effective amount of the composition provides a quantity of fenofibrate active species to a fasted human patient in need of treatment by fenofibrate that is greater than 80% of the quantity of fenofibrate active species provided by the same amount of the composition when administered to the same patient who has been fed a high fat meal consisting of at least 1000 calories, 50% of which are from fat. The present invention also provides a method of treatment of dislipidemia and dislipoproteinemia in a mammal consisting of administering a therapeutically effective oral dosage form comprising microparticles of a solid fibrate that are stabilized by a phospholipid surface active substance wherein the dosage form provides into the blood of the patient in a fasted state a therapeutically effective amount of a fibrate active species that is at least 90% of the AUC amount of the fibrate active species provided by the same dosage form into the blood of the same patient when the patient is in a fed state.

US Patent:

20060210622, Sep 21, 2006

Filed:

Nov 14, 2005

Appl. No.:

11/272902

Inventors:

Gary Pace - Winchester MA, US
Awadhesh Mishra - Verdun, CA
Robert Snow - West Chester PA, US

International Classification:

A61K 9/64
A61K 9/26

US Classification:

424456000, 424469000

Abstract:

This invention disclosure relates to compositions for the delivery of stable surface modified sub-micron and micron sized particles of water-insoluble biologically active substances from a non-aqueous medium that self-disperses on exposure to an aqueous environment.

US Patent:

20210002601, Jan 7, 2021

Filed:

Sep 21, 2020

Appl. No.:

17/027017

Inventors:

- Cambridge MA, US
Robert Snow - Southborough MA, US

Assignee:

Genzyme Corporation - Cambridge MA

International Classification:

C12M 1/12
C12M 1/26
C12M 1/00
C12P 21/00

Abstract:

Provided herein are isolation processes and the associated hardware to allow fluid streams to be isolated from a sterilized system (e.g., a sterile process vessel) that contains a sterile process. The isolation processes described herein allow for continuous removal of fluid streams (e.g., waste streams, liquid containing recombinant therapeutic proteins) from a sterilized system (e.g., a biological manufacturing system), which provides for less manual manipulation of the sterilized system and a decreased risk of contaminating the sterilized system.

US Patent:

20160115438, Apr 28, 2016

Filed:

Oct 20, 2015

Appl. No.:

14/918107

Inventors:

- Cambridge MA, US
Robert Snow - Southborough MA, US

International Classification:

C12M 1/12
C12M 1/00
C12P 21/00

Abstract:

Provided herein are isolation processes and the associated hardware to allow fluid streams to be isolated from a sterilized system (e.g., a sterile process vessel) that contains a sterile process. The isolation processes described herein allow for continuous removal of fluid streams (e.g., waste streams, liquid containing recombinant therapeutic proteins) from a sterilized system (e.g., a biological manufacturing system), which provides for less manual manipulation of the sterilized system and a decreased risk of contaminating the sterilized system.